DD02S / D&D Pharmatech - LARVOL DELTA

D&D Pharmatech’s US partner starts North American study for oral GLP-1 obesity drug (Korea Biomedical Review) - "D&D Pharmatech said Friday that its U.S. partner Metsera has begun the North American clinical trial of DD02S (MET-002 in trademark name), an oral GLP-1 obesity treatment....The study will evaluate the safety, tolerability, efficacy and pharmacokinetics of DD02S following single and multiple ascending oral doses in overweight and obese adults. The study will be conducted in overweight and obese adults."

Licensing / partnership • Metabolic Disorders • Obesity